ITI Pharma & Healthcare Fund - Growth - Direct Plan

Other Plans and Options
  • 0.27 %Nav, as on 10-06-2025

  • Previous Nav

  • Net Change on 10-06-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The investment objective of the scheme is to seek to generate long term capital appreciation throughinvesting in equity and equity related securities of companies engaged in Pharma and Healthcare.However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
Nifty Healthcare Index - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Direct Plan - Cumulative Option Jul 13, 2018 24.45 29.61 26.08 1.06 5,295.32
Tata India Pharma & Healthcare Fund-Direct Plan-Growth Dec 28, 2015 16.42 25.65 22.86 0.63 1,222.72
UTI Healthcare Fund - Direct Plan - Growth Option Jan 01, 2013 22.66 26.57 22.79 1.28 1,037.49

Fund Holdings as on 31-May-2025

  • Sun Pharmaceutical Industries Limited

  • Divi's Laboratories Limited

  • Max Healthcare Institute Limited

  • Lupin Limited

  • Apollo Hospitals Enterprise Limited

  • Cohance Lifesciences Limited

  • Aurobindo Pharma Limited

  • Torrent Pharmaceuticals Limited

  • Aster DM Healthcare Limited

  • Mankind Pharma Limited

  • Alkem Laboratories Limited

  • Fortis Healthcare Limited

  • Abbott India Limited

  • Wockhardt Limited

  • Granules India Limited

  • Neuland Laboratories Limited

  • FDC Limited

  • Healthcare Global Enterprises Limited

  • Supriya Lifescience Limited

  • Sumitomo Chemical India Limited

  • Sagility India Limited

  • Rainbow Childrens Medicare Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Vijaya Diagnostic Centre Limited

  • Shilpa Medicare Limited

  • Dr. Reddy's Laboratories Limited

  • Gland Pharma Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • UPL Limited

  • Onesource Specialty Pharma Limited

  • Caplin Point Laboratories Limited

  • Linde India Limited

  • Orchid Pharma Limited

  • Cipla Limited

  • Sai Life Sciences Limited

  • Strides Pharma Science Limited

  • Laurus Labs Limited

  • SRF Limited

  • TTK Healthcare Limited

  • Net Receivables / (Payables)

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

  • Pesticides & Agrochemicals

  • Chemicals

  • Industrial Gases & Fuels

View More

Fund Manager

  • Cash

  • Equity

View More

About ITI Pharma & Healthcare Fund

Scheme Analysis

ITI Pharma & Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to ITI Mutual Fund. It was launched on 08-Nov-2021 and currently has an AUM of ₹220.85 crore. ITI Pharma & Healthcare Fund is benchmarked against NIFTY 50 - TRI as primary index and Nifty Healthcare Index - TRI as secondary index.

The NAV of ITI Pharma & Healthcare Fund ended up ₹0.05(0.27%)yesterday to ₹17.4266.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The ITI Pharma & Healthcare Fund is managed by Dhimant Shah and Rohan Korde.

Fund House Contact

ITI House, 36, R K Shirodkar Marg, Parel Mumbai - 400 012

022-69153500
mfassist@itiorg.com
www.itiamc.com